Drugs / Xanomeline/trospium
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT07084831 | Jan 2027 → Jan 2029 expected | cognitive impairment with or without cerebellar ataxia, schizophrenia | European Group for Research In Schizophrenia | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Xanomeline/trospium | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07084831 ↗ |
| Route | Oral | “Participants will receive oral xanomeline/trospium during the trial” NCT07084831 ↗ |